ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

ORIC Pharmaceuticals (ORIC) shares surged over 20% pre-market following the release of positive preliminary data from its Phase Ib study of ORIC-944 in combination with J&J’s Erleada or Bayer’s Nubeqa for metastatic castration-resistant prostate cancer (mCRPC); the study showed a 47% confirmed PSA50 response rate and a 24% confirmed PSA90 response rate in previously treated patients. ORIC expects to complete the dose exploration phase by mid-2025 and initiate a global Phase III study in the first half of 2026, supported by a concurrent $125 million private placement to fund operations into the second half of 2027.

Analysis

ORIC Pharmaceuticals (ORIC) experienced a significant pre-market stock surge exceeding 20% following the announcement of positive preliminary data from its Phase Ib study of ORIC-944, a novel, once-daily candidate for metastatic castration-resistant prostate cancer (mCRPC). The study, evaluating ORIC-944 in combination with J&J’s Erleada or Bayer’s Nubeqa, demonstrated promising efficacy and safety, with data as of May 9, 2025, from 17 previously-treated patients showing a 59% PSA50 response rate (47% confirmed) and a 24% PSA90 response rate (all confirmed). These responses were observed across all ORIC-944 dose levels and with both combination agents, and the treatment was well-tolerated with only mild to moderate adverse events. This positive clinical development contrasts with ORIC's year-to-date share decline of 26% prior to this news, compared to the industry's 4.8% decline. ORIC plans to complete the Phase Ib dose exploration by mid-2025, proceed to dose optimization in the second half of 2025, and initiate a global Phase III study in the first half of 2026. Concurrently, the company announced a $125 million private placement, expected to fund operations into the second half of 2027, covering expenses through the anticipated Phase III primary endpoint readout. Beyond ORIC-944, ORIC's pipeline includes ORIC-114 for non-small-cell lung cancer. The article also highlights Amarin (AMRN) as a Zacks Rank #2 (Buy) stock in the biotech sector, noting narrowed loss per share estimates for 2025 and 2026, a 16.4% year-to-date share gain, and a recent history of positive earnings surprises.

Key Decisions for Investors

• Investors should acknowledge the significant positive clinical data for ORIC-944 and the resultant stock appreciation, while carefully weighing this against the early-stage nature of the asset and the inherent volatility associated with biotech clinical development.
• The announced $125 million private placement significantly de-risks ORIC's near-term financial outlook by extending its cash runway through anticipated pivotal Phase III data, a crucial factor for assessing the company's sustainability and investment profile.
• Closely monitor ORIC's execution on its clinical development timeline for ORIC-944, particularly the completion of Phase Ib dose exploration by mid-2025, subsequent dose optimization results, and the initiation of the global Phase III study in H1 2026, as these milestones will be critical inflection points for valuation.
• Note the article's specific mention of Amarin (AMRN) as a 'better-ranked' biotech stock with positive estimate revisions and recent performance, potentially warranting further due diligence as a comparative or alternative investment opportunity within the sector.